Search Results

192 results

  1. CORESTA Meeting, Smoke Science/Product Technology, 2019, Hamburg, ST 44

    Lung biomarkers of harm/effect for tobacco regulatory research: opportunities and challenges – a literature review

    MAKENA P.(1); EDMISTON J.(2); BEATTIE E.(3); MASON E.(4); McEWAN M.(5); PRASAD K.(5)
    (1) RAI Services Company, Winston-Salem, NC, U.S.A.; (2) Altria Client Services LLC, Richmond, VA, U.S.A.; (3) Cliantha Research Limited, Canada; (4) Imperial Brands PLC, Bristol, U.K.; (5) British American Tobacco (Investments) Limited, Southampton, U.K.
    Biomarkers of potential harm (BoPH) are indicators of biological perturbations in response to smoking, which may contribute to smoking-related disease. In this review, a project of the CORESTA Biomarkers Sub-Group, we critically assessed the available ...
  2. CORESTA Meeting, Smoke Science/Product Technology, 2019, Hamburg, ST Sustainability Forum

    Smoke-Techno Sustainability Forum

    RUSSELL C.(1); THOMPSON J.(2); RAVERDY-LAMBERT D.(3); MÜHLBACHER I.(4); COLARD S.(5)
    (1) Centre for Substance Use Research (CSUR), Glasgow, Scotland, U.K.; (2) Imperial Brands PLC, Bristol, U.K.; (3) SWM International, Le Mans, France; (4) Ökolab, Vienna, Austria; (5) CORESTA, Paris, France
    In 2015, the United Nations published 17 sustainable development goals and their corresponding targets to be achieved by 2030. Like other sectors, the tobacco and alternative product sectors are likely to impact most of the goals. Consequently, it is ...
  3. CORESTA Meeting, Smoke Science/Product Technology, 2019, Hamburg, STPOST 33

    Quantitative risk assessment (QRA) indicates reduced risk potential for carcinogenic and non-carcinogenic effects of the aerosol of the next generation products (NGPs) compared to reference cigarettes

    AYALA-FIERRO F.(1); CZEKALA L.(2); SIMMS L.(2); RUDD K.(2); CAVA G.(2); STEVENSON M.(2)
    (1) ITG Brands LLC, Greensboro, NC, U.S.A.; (2) Imperial Brands PLC, Bristol, U.K.
    In order to understand the potential relative health risks of NGPs compared to cigarettes, we compared the relative risks of aerosols from tobacco-containing and tobacco-free NGPs to the smoke generated from a reference cigarette. Quantitative Risk ...
  4. CORESTA Meeting, Smoke Science/Product Technology, 2019, Hamburg, STPOST 34

    Next generation product aerosols induce lower biological activity than combusted cigarettes: a comparison of in vitro cell migration in the scratch wound assay

    RUDD K.(1); BUDDE J.(2); TRELLES STICKEN E.(2); WIECZOREK R.(2); SIMMS L.(1); STEVENSON M.(1)
    (1) Imperial Brands PLC, Bristol, U.K.; (2) Reemtsma Cigarettenfabriken GmbH (an Imperial Brands PLC Company), Hamburg, Germany
    Smoking combustible cigarettes is a cause of serious diseases in smokers, including heart disease. There are many commercially available next generation products (NGPs), such as tobacco-free e-vapour products, aiming to provide an alternative to smoking ...
  5. CORESTA Meeting, Smoke Science/Product Technology, 2019, Hamburg, STPOST 49

    The CORESTA in vitro test battery for combustible tobacco products: update from the 2004 Rationale and Strategy Report

    LEE K.M.(1); JORDAN K.G.(2); WIECZOREK R.(3); MOENNIKES O.(4); CLEMENTS J.(5); CROOKS I.(6); HASHIZUME T.(7); MILLER J.(8); WEBER E.(9); YOSHINO K.(7)
    (1) Altria Client Services, Richmond, VA, U.S.A.; (2) RAI Services Company, Winston-Salem, NC, U.S.A.; (3) Imperial Brands, Reemtsma Cigarettenfabriken GmbH, Hamburg, Germany; (4) PMI R&D, Philip Morris Products S.A., Neuchâtel, Switzerland; (5) Covance Laboratories Ltd, Harrogate, U.K.; (6) British American Tobacco (Investments) Ltd, R&D, Southampton, U.K.; (7) Japan Tobacco Inc., Yokohama, Kanagawa, Japan; (8) JT International SA, Geneva, Switzerland; (9) Ökolab, Vienna, Austria
    In 2004, the CORESTA In Vitro Toxicity Task Force issued a rationale and strategy report, commonly known as “the CORESTA in vitro test battery guideline”. The goals of this guideline were to: 1) develop the rationale and strategy for conducting in vitro ...
  6. CORESTA Meeting, Smoke Science/Product Technology, 2019, Hamburg, STW 01

    The application of in vitro Toxicity Testing in 21 Century (TT21C) for next generation products

    SIMMS L.(1); TRELLES STICKEN E.(2)
    (1) Imperial Brands PLC, Bristol, U.K.; (2) Reemtsma Cigarettenfabriken GmbH (an Imperial Brands PLC Company), Hamburg, Germany
    The aim is to demonstrate the feasibility of TT21C in vitro methods as part of an overall assessment framework for next generation products (NGP). TT21C methodologies can be used to assess harm reduction potential of NGPs using human-derived cellular ...
  7. CORESTA Congress, Kunming, 2018, Agronomy/Phytopathology Groups, APPOST 30

    Nicotine reduction and consumer perception: a scientific approach for quantifying possible impact of low nicotine cigarettes on consumer behaviour

    GUO Mengran(1); VERRON T.(1); DORLHAC de BORNE F.(2); PRITCHARD J.(3); COLARD S.(1)
    (1) SEITA - Imperial Brands plc, Paris, France; (2) Imperial Tobacco Limited, Leaf Research, Bergerac, France; (3) Imperial Brands, Bristol, U.K.
    In 2015, the WHO Study Group on Tobacco Product Regulation (TobReg) issued an advisory note recommending a strategy to reduce nicotine in tobacco to levels which would not be sufficient to lead to the development and/or maintenance of addiction. In the US ...
  8. CORESTA Congress, Kunming, 2018, Smoke Science/Product Technology Groups, ST 60

    Assessing changes in biomarkers of effect in smokers who switch to a closed system electronic cigarette

    MASON L.; CAHOURS X.; O'CONNELL G.; WALELE T.
    Imperial Brands, Bristol, U.K.
    Previous studies have demonstrated that when smokers switch to an electronic cigarette, they are exposed to significantly lower levels of carcinogens and toxicants. As a result, there is a reported significant reduction in biomarkers of exposure to levels ...
  9. CORESTA Congress, Kunming, 2018, Smoke Science/Product Technology Groups, STPOST 39

    The use of high content screening (HCS) in human primary lung cells to assess e-liquids of differing flavors and nicotine concentrations

    SIMMS L.(1); CZEKALA L.(1); STEVENSON M.(1); PHILLIPS G.(1); WALELE T.(2)
    (1) Imperial Brands, Bristol, U.K.; (2) Fontem Ventures, Amsterdam, The Netherlands
    Due to the current scientific debate and evolving regulatory landscape, new assays are needed to quickly determine the subtle biological response of e-liquids for both stewardship and product development purposes. For stewardship, all ingredients in the e ...